Traverse Biosciences, Stony Brook, NY

Traverse Biosciences is commercializing novel drug candidates for the treatment of inflammatory diseases and related conditions affecting humans and companion animals. Its lead candidate, TRB-N0224, is envisioned as the first FDA-approved, once-daily, edible prescription medication for the prevention and control of canine periodontal disease.